Neil Shneider, MD, PhD, discusses how patients have fared in the phase three trial of tofersen and how the drug will impact ALS treatment in the future.
Columbia’s cell therapy lab, which creates customized cell therapies, is testing its first product, T cells trained to fight dangerous infections in transplant patients.